A Phase 2 interventional study of selinexor in Richter's Transformation, sponsored by Karyopharm Therapeutics Inc. Terminated at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior chronic lymphocytic leukemia (CLL), after at least one chemo-immunotherapy regimen for CLL.
Multi-center, phase 2, single arm, open-label study of oral selinexor monotherapy in patients with Richter's Transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including diffuse large B-cell (DLBCL) and immunoblastic variants. Eligible patients must have had at least one prior regimen for CLL. Approximately 50 patients are anticipated to be treated in this study. Eligible patients following screening will receive selinexor orally twice weekly at a dose of 60 mg. The selinexor dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated. Patients may continue in multiple treatment cycles at a given dose; there is no maximum treatment duration. Each cycle is 28 days. Dose adjustments will be made as appropriate by the investigator.
Patients who were treated twice weekly for weeks 1-3 under a previous version of the protocol may, at the discretion of the investigator, have had the frequency of selinexor dosing increased to twice weekly for weeks 1-4. If there was no contraindicated toxicity, the selinexor dose may have been increased to 80 mg at Cycle 3.
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral tablets * 10 mg \& 25 mg (bottled); or * 20 mg (blister pack)
Drug: selinexor
* 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0). * 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0). * 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0). * 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0).
Also known as: KPT-330
Percentage of Participants With Overall Response (Overall Response Rate)
Overall Response Rate (ORR) is defined as the point estimate of the percentage of patients who have complete response (CR) or partial response (PR). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. CR was defined as disappearance of all evidence of disease, and PR was defined as ≥ 50% regression of measurable disease and no new sites.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Number of Participants With Complete Response (CR)
Number of patients who achieved CR (complete disappearance of all detectable evidence of disease). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Number of Participants With Partial Response (PR)
Number of patients whose best overall response to study treatment was PR (≥ 50% regression of measurable disease and no new sites). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Number of Participants With Stable Disease (SD)
Number of patients whose best overall response to study treatment was SD (failure to attain criteria for CR or PR, or to meet criteria for PD). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Number of Participants With Progressive Disease (PD)
Number of patients whose best overall response to study treatment was PD (any new lesion or increase by ≥ 50% of previously involved sites from nadir). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Number of Participants With Not Evaluable (NE) Response
Number of patients who could not be assessed quantitatively for disease response for any reason.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Percentage of Participants With Disease Control (Disease Control Rate)
Disease Control Rate (DCR) is defined as the percentage of patients who achieved CR, PR, or SD lasting for at least 8 weeks. CR was defined as disappearance of all evidence of disease. PR was defined as ≥ 50% regression of measurable disease and no new sites. SD was defined as failure to attain criteria for CR or PR, or to meet criteria for PD. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
Duration of Progression Free Survival (PFS)
Number of days calculated from date of start of study therapy to date of progression based on IWG criteria, or date of death if progression did not occur. Patients who dropped out prior to study end without evidence of disease progression were censored at the day they were last known to be alive. Patients without documented disease progression or recurrence were censored at the date of last disease assessment. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. .
Time frame: Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.
This multicenter study was conducted at 30 clinical investigative sites in the United States and Europe. Of the 30 investigative sites, 15 sites enrolled a total of 27 patients in the study. * Date first patient enrolled: 14 November 2014 * Date last patient completed: 31 August 2016
| Milestone | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) |
|---|---|---|---|
| Started | 3 | 15 | 8 |
| Completed | 0 | 0 | 0 |
| Not completed | 3 | 15 | 8 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Death | 1 | 7 | 2 |
| Withdrew: Disease progression | 1 | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
| Withdrew: Patient's wish | 0 | 2 | 0 |
| Withdrew: Sponsor terminated study | 0 | 1 | 1 |
| Withdrew: Non-compliance | 0 | 0 | 1 |
Overall Response Rate (ORR) is defined as the point estimate of the percentage of patients who have complete response (CR) or partial response (PR). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. CR was defined as disappearance of all evidence of disease, and PR was defined as ≥ 50% regression of measurable disease and no new sites.
| Percentage of participants | Selinexor |
|---|---|
| Percentage of Participants With Overall Response (Overall Response Rate) | 4 (0.1 to 20.4) |
Number of patients who achieved CR (complete disappearance of all detectable evidence of disease). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
| Participants | Selinexor |
|---|---|
| Number of Participants With Complete Response (CR) | 0 |
Number of patients whose best overall response to study treatment was PR (≥ 50% regression of measurable disease and no new sites). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
| Participants | Selinexor |
|---|---|
| Number of Participants With Partial Response (PR) | 1 |
Number of patients whose best overall response to study treatment was SD (failure to attain criteria for CR or PR, or to meet criteria for PD). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
| Participants | Selinexor |
|---|---|
| Number of Participants With Stable Disease (SD) | 6 |
Number of patients whose best overall response to study treatment was PD (any new lesion or increase by ≥ 50% of previously involved sites from nadir). Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
| Participants | Selinexor |
|---|---|
| Number of Participants With Progressive Disease (PD) | 7 |
Number of patients who could not be assessed quantitatively for disease response for any reason.
| Participants | Selinexor |
|---|---|
| Number of Participants With Not Evaluable (NE) Response | 11 |
Disease Control Rate (DCR) is defined as the percentage of patients who achieved CR, PR, or SD lasting for at least 8 weeks. CR was defined as disappearance of all evidence of disease. PR was defined as ≥ 50% regression of measurable disease and no new sites. SD was defined as failure to attain criteria for CR or PR, or to meet criteria for PD. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests.
| Percentage of participants | Selinexor |
|---|---|
| Percentage of Participants With Disease Control (Disease Control Rate) | 28.0 (12.1 to 49.4) |
Number of days calculated from date of start of study therapy to date of progression based on IWG criteria, or date of death if progression did not occur. Patients who dropped out prior to study end without evidence of disease progression were censored at the day they were last known to be alive. Patients without documented disease progression or recurrence were censored at the date of last disease assessment. Disease response was assessed using the International Working Group (IWG) Response Criteria for non-Hodgkin's lymphoma (Cheson 2007), including assessment of lymph node, spleen and liver lesions by PET (positron emission tomography) scan and assessment of bone marrow biopsies by morphologic, immunohistochemistry, and flow cytometry tests. .
| Days | Selinexor |
|---|---|
| Duration of Progression Free Survival (PFS) | 38.0 (22.0 to 86.0) |
Collected over Treatment-emergent AEs were collected from the first day of dosing (Cycle 1 Day 1) through the 30-day follow-up.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selinexor 60 mg/m² (8 Doses/Cycle) | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Selinexor 60 mg (6 Doses/Cycle) | 8/15 (53.3%) | 9/15 (60%) | 15/15 (100%) |
| Selinexor 60 mg (8 Doses/Cycle) | 2/8 (25%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Event | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 0/15 | 1/8 |
| AstheniaGeneral disorders | 1/3 | 0/15 | 0/8 |
| FatigueGeneral disorders | 1/3 | 0/15 | 0/8 |
| Mucosal InflammationGeneral disorders | 1/3 | 0/15 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 1/3 | 0/15 | 0/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 1/15 | 0/8 |
| Acute Kidney InjuryRenal and urinary disorders | 1/3 | 0/15 | 0/8 |
| SepsisInfections and infestations | 0/3 | 1/15 | 2/8 |
| Deep Vein ThrombosisVascular disorders | 0/3 | 0/15 | 1/8 |
| Clostridium Test PositiveInvestigations | 0/3 | 0/15 | 1/8 |
| Event | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 8/15 | 3/8 |
| FatigueGeneral disorders | 2/3 | 4/15 | 2/8 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/3 | 5/15 | 2/8 |
| HypotensionVascular disorders | 2/3 | 0/15 | 2/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 8/15 | 5/8 |
| DizzinessNervous system disorders | 0/3 | 1/15 | 4/8 |
| VomitingGastrointestinal disorders | 1/3 | 7/15 | 1/8 |
| PyrexiaGeneral disorders | 1/3 | 6/15 | 2/8 |
| DiarrheaGastrointestinal disorders | 1/3 | 5/15 | 3/8 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 3/15 | 3/8 |
Safety Population, consisting of all patients who received any amount of study medication.
| Age, Continuous(years) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| Median | 68.0 (66 to 74) | 68.0 (41 to 77) | 69.0 (65 to 79) | 68.0 (41 to 79) |
| Sex: Female, Male(Participants) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| Female | 2 | 3 | 4 | 9 |
| Male | 1 | 12 | 4 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 1 | 14 | 8 | 23 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 15 | 8 | 26 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| ECOG score(Participants) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| Score=0 | 0 | 5 | 2 | 7 |
| Score=1 | 3 | 6 | 4 | 13 |
| Score=2 | 0 | 4 | 1 | 5 |
| Missing | 0 | 0 | 1 | 1 |
| Weight(kg) | Selinexor 60 mg/m² (8 Doses/Cycle) | Selinexor 60 mg (6 Doses/Cycle) | Selinexor 60 mg (8 Doses/Cycle) | Total |
|---|---|---|---|---|
| Median | 56.5 (52.3 to 96.0) | 76.5 (51.9 to 115.5) | 73.05 (46.4 to 88.1) | 74.40 (46.4 to 115.5) |
Plan to share: Yes
Ran from Nov 2014 to primary completion in Aug 2016, 21 months.
Results were first posted in Feb 2020, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor